@article{15f70a16a60842f39030e41afeaf84e0,
title = "Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?",
keywords = "Adalimumab, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibody Formation, Humans, Immunologic Factors, Infliximab, Treatment Outcome, Letter",
author = "K Bendtzen and C Steenholdt",
year = "2017",
month = mar,
doi = "10.1111/apt.13921",
language = "English",
volume = "45",
pages = "759--760",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",
}